Leveraging the company’s sustainable design expertise and over 50 years of experience in the development of respiratory drug delivery devices, the new inhalation products help deliver a better healthcare experience by improving quality of care while helping to reduce costs and supporting the circular economy.
At the conference, Berry will show a range of models from its extensive portfolio of dry powder inhalers (DPIs), pressurized metered dose inhalers (pMDIs) with or without dose indicators, breath-actuated inhalers, and digital inhalers.
A major highlight on the stand will be the company’s newly launched PneumoHaler, a lightweight, breath-actuated, multi-dose inhaler with a dose indicator for the effective management of asthma and chronic obstructive pulmonary disease (COPD). Designed to provide a ready-to-use solution for new inhalation treatments, the PneumoHaler eliminates the need for pharmaceutical companies to develop their own platforms, enabling the delivery of faster-to-market solutions. Equally important, the PneumoHaler helps enhance medication adherence caused by poor user technique of pMDIs.
Significant recent introductions in Berry’s DPI range include the RS01-X single-dose DPI with built-in sensors and digital services to track inhaler use and help improve adherence and technique, and the RS01 Size 2 capsule-based inhaler, which meets the increased demand for higher dose devices for the pulmonary delivery of systemic treatments and highly engineered, low-density powder formulations.
Berry will also demonstrate its market leadership in the CDMO of customized devices based on customers’ IP. Both standard and bespoke solutions can be developed and supplied from the company’s three facilities in Osnago (Italy), Mellrichstadt (Germany), and Bengaluru (Bangalore, India), providing a global reach and fast response.
“At Berry, we think Beyond Drug Delivery, and we help our customers Do Better, By Dosing better,” said Arturo Cubí, Business Development Director – Global Healthcare for Berry Global.
“This is our commitment to create patient-centric drug delivery inhalation solutions that enhance the user experience, improve disease management, and minimize environmental impact. We look forward to discussing customers’ specific requirements during DDL 2023.”
Learn more about the products and solutions offered in the global healthcare market.